GSK Researchers Sequence Drug Target Genes to Help ID Drug Repositioning Opportunities | GenomeWeb

Researchers from GlaxoSmithKline have sequenced 202 drug target genes in more than 14,000 individuals in order to look for variants that would suggest novel targets or a way to repurpose existing drugs.

The team is now following up on the results, which were published earlier this month in Science.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.